Biomarin Rises On Unusually High Volume (BMRN)
NEW YORK (
) --
(Nasdaq:
) is trading at unusually high volume Friday with three million shares changing hands. It is currently at two times its average daily volume and trading up $4.62 (+7.7%) at $64.92 as of 3:45 p.m. ET.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Biomarin has a market cap of $8.42 billion and is part of the health care sector and drugs industry. Shares are up 23.1% year to date as of the close of trading on Thursday.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
TheStreet Ratings rates
Biomarin
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full
.
See all heavy volume stocks in our
stocks moving on unusual volume list
or get investment ideas from our
.
.
null